To test this possibility, we examined BRAF essentiality in melanoma, in which BRAF mutations are predictive of sensitivity to BRAF inhibitors (Chapman et al. 2011), and in colon cancer, in which BRAF mutations are less prevalent and predict only a weak response to BRAF inhibitors (Prahallad et al. 2012). The gene discussed is BRAF; the disease is melanoma.